A study to prevent rebleeding after initial successful primary endoscopic haemostasis of a bleeding peptic ulcer

Study identifier:D961DC00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to assess prevention of rebleeding in subjects that have undergone successful primary endoscopic haemostasis of a bleeding peptic ulcer – the PUB study.

Medical condition

Gastrointestinal Hemorrhage

Phase

Phase 3

Healthy volunteers

No

Study drug

Esomeprazole

Sex

All

Actual Enrollment

1312

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2005
Primary Completion Date: 01 Dec 2007
Study Completion Date: 01 Dec 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria